Search Results - cancer+therapies

8 Results

Sort By:

Modified Ectodomain of Human EGFR as a Potential Anticancer Agent

Development of a protein that attenuates EGFR and/or EGFR family members and is comprised of a modified EGFR ectodomain. The protein inhibits signaling via the EGFR and/or EGFR family members. The protein includes a portion of the EGFR (or EGFR family member) and the "U" region epitope of EGFR related protein (ERRP), wherein the portion of the EGFR...

Published: 2/6/2014 | Inventor(s): Adhip Majumdar, Arun Rishi, Yingjie Yu

Keywords(s): Breast Cancer, Cancer, Cancer Therapies, Disease, Drug Target, Protein, Therapeutics

Category(s): Life Science, Biologicals, Diseases, Oncology

Translation Regulated (TR)-Mediated Gene Expression: Novel Expression and Reporter Vectors

This is a cell based vector system that is able to monitor the transition, in cell lines, from Cap dependent to Cap independent translation. This shift is critical in determining if a cell, that is placed under significant stress (such as treatment with a chemotherapeutic agent), recovers or undergoes programmed cell death (apoptosis). This information...

Published: 2/6/2014 | Inventor(s): Leon Carlock, Maria Cypher

Keywords(s): Animal Model, Anti-cancer, Cancer, Cancer risk, Cancer Therapies, Diagnostics, Imaging, Therapeutics

Category(s): Life Science, Diagnostics, Research tools, Assays, Cell lines

New Immunotherapies for Cancer

Background Wayne State University researchers have developed a novel strategy to fight cancer and eradicate tumors through stimulation of the immune system. Curing cancer via the activation of patients’ immune system is considered an ideal strategy due to the potentially high potency and specificity of the human immune system to eradicate tumors....

Published: 3/31/2014 | Inventor(s): Zhongwu Guo, Qianli Wang, Shouchu Tang

Keywords(s): Cancer Therapies, Drug Delivery, Pharmaceuticals, Therapeutics, Vaccines

Category(s): Therapeutics, Life Science, Diseases, Oncology

Folate Receptor Targeted Therapeutics for Cancer

Collaborative researchers at WSU and Duquesne University have developed a series of novel folate analogs that show selective toxicity toward tumor cells expressing high levels of the surface protein folate receptor. Typically, normal cells express low levels of folate receptors or such receptors exhibit apical localization and are not exposed to...

Published: 2/6/2014 | Inventor(s): Larry Matherly, Aleem Gangjee

Keywords(s): Biotechnology, Cancer, Cancer Therapies

Category(s): Therapeutics, Life Science, Oncology

Tumor Targeting by Small Molecule Therapeutics for a Proton-Coupled Folate Transporter (PCFT)

WSU and Duquesne University scientist have isolated a unique series of pyrrolopyrimidine antifolate analogs that show selective cytotoxicity toward solid tumors such as ovarian, prostate or breast cancer cells that express the low pH “proton-coupled folate transporter” (PCFT). The acidic pH optimum (pH 5.5-6.5) of PCFT makes it an ideal target...

Published: 3/31/2014 | Inventor(s): Larry Matherly, Aleem Gangjee

Keywords(s): Analog or Analogue, Breast Cancer, Cancer Therapies, Drug Delivery, Ovarian Cancer, Prostate Cancer

Category(s): Therapeutics, Life Science, Small molecule, Oncology

Method For Treating and/or Imaging Breast Cancer Using Radioactive Iodine

This invention involves treating a breast cancer patient by the administration of a radioisotope of iodine in a dosage of between 5 and 50 milliCuries over the course of a day. The therapeutic composition is designed for mammary tissue uptake and includes an inorganic radioactive iodide salt (e.g., alkali metal, alkali earth or transition metal...

Published: 3/31/2014 | Inventor(s): James Rillema

Keywords(s): Anti-cancer, Breast Cancer, Cancer Therapies, Imaging, Therapeutics

Category(s): Therapeutics, Life Science, Oncology, Receptors/targets, Diagnostic, Imaging

GlyB4 Fusion with Neuregulin Heparin-Targeting Domain to Block Neuregulin Signaling

We have harnessed this natural targeting ability of NRG by fusing the HBD of NRG to soluble HER4. This fusion protein retains high affinity heparin binding to heparin and to cells that express heparan sulfates resulting in a more potent NRG antagonist. In vivo, it is targeted to peripheral nerve segments where it blocks the activity of NRG as a Schwann...

Published: 2/6/2014 | Inventor(s): Jeffrey Loeb, Qunfang Lee

Keywords(s): Anti-cancer, Biotechnology, Cancer risk, Cancer Therapies, Drug Delivery, Drug Target, Epilepsy

Category(s): Life Science, Drug Delivery, Other

Dual action nanocarrier combining CXCR4 antagonist and polyplex gene delivery for treatment of metastatic cancer and other diseases

Novel bio-reducible polymer compositions which combine the ability to act as a CXCR4 antagonist and simultaneously provide enhanced gene delivery through the formation of inert nanocarrier polyplexes have been developed. As would be expected for biodegradable polymers, the cytotoxicity of these nanocarrier compositions are very low with measured IC50...

Published: 3/31/2014 | Inventor(s): David Oupicky, Jing Li

Keywords(s): Cancer, Cancer Therapies, Compound, Drug Delivery, Drug Target, Formulation, Imaging, Nanomaterials, Pharmaceuticals, Therapeutics

Category(s): Drug Delivery, Gene Therapy, Therapeutics, Life Science, Oncology, Nano-based, Metabolic disorders, Biologicals